Abbott Laboratories : 1Q 2020 Earnings Infographic

Q 1 2 0 2 0 F I N A N C I A L R E S U LT S

OUR DIVERSIFIED MODEL

DELIVERED IN Q1

SALES WORLDWIDE

$7.7B		+4.3%1
in sales		on organic basis*

SALES PERFORMANCE

ACROSS ABBOTT2

ON AN ORGANIC BASIS*

+7.3%+9.3%

N U T R I T I O NESTABLISHED PHARMACEUTICALS

+2.9%	+0.7%
MEDICAL DEVICES	DIAGNOSTICS

HELPING TO STEM

THE SPREAD OF COVID -19

DETECTING THE VIRUS

• Launched newlab-based antibody blood test, the SARS-CoV-2IgGtest, available now in the U.S. for the detection of the antibody that identifies if a person has had the novel coronavirus (COVID-19)
• Launched two newCOVID-19 detection tests: the rapid point-of-careID NOW™ COVID-19test, delivering positive results

in as little as five minutes, as well as the m2000™ RealTimeSARS-CoV-2EUAlaboratory test for hospital and reference labs

• Expect to produce millions ofCOVID-19 tests per month, deploying them to areas of greatest impact

SUPPORTING IMPACTED COMMUNITIES

• Donating funding and products to support frontline healthcare workers, families and communities

PROTECTING OUR

EMPLOYEES

• Taken steps at our sites to limit exposure
• Further enhanced facility safety for employees working to continue to supply our vital healthcare products

O U R P R O D U C T P O R T F O L I O I S S T R O N G A N D

DRIVING THE FUTURE OF HEALTHCARE

FREEST YLE
LIBRE	%3
SALES	63
UP
ON ORGANIC BASIS*	114 mg/dL

FreeStyle Libre14 day system† can now be used in hospital settings during the COVID-19 pandemic, permitting frontline healthcare workers to remotely monitor patients with diabetes receiving inpatient care, who can scan themselves

Received expanded reimbursement in Japan to include people with Type 2 diabetes using multiple daily injections of insulin

Announced collaboration with Insulet to create an integrated insulin delivery platform

H E A R T

FAILURE

SALES 11%4

UP

ON ORGANIC BASIS*

Received U.S. FDA approval for less-invasive surgical approach for heart failure patients

STRUCTURAL

HEART

CE MARK FOR TWO DEVICES

TO TREAT CHALLENGING FORMS OF HEART DISEASE

TriClipTM, world's first minimally invasive, clip-based repair device for the treatment of tricuspid regurgitation, or leaky tricuspid valve

TendyneTM, first-of-its-kind technology that treats mitral regurgitation in patients requiring a heart valve replacement, without open-heart surgery

Tr i C l i p

Te n d y n e

• Organic sales growth excludes impact of foreign exchange. For full financial data and reconciliation ofnon-GAAP measures, please see our press release dated April 16, 2020, available at www.abbottinvestor.com.

† Find important safety information about the FreeStyle Libre 14 day system: https://www.freestylelibre.us/safety-information.html

1.On a GAAP basis, Abbott sales increased 2.5%. 2.On a GAAP basis, Nutrition sales increased 6.3%; Established Pharmaceuticals sales increased 5.2%; Medical Devices sales increased 1.4%; and Diagnostics sales decreased 0.8%. 3.On a GAAP basis, FreeStyle Libre sales increased 59%. 4.On a GAAP basis, Heart Failure sales increased 10%.

FORWARD-LOOKING STATEMENTS

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties, including the impact of the COVID-19 pandemic on Abbott's operations and financial results, that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors'' to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2019, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.